Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

BACKGROUND: In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. Due to a lack of clinical evidence and expertise, managing these AEs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahaghi, Franck F., Safdar, Zeenat, Brown, Anne Whitney, de Andrade, Joao A., Flaherty, Kevin R., Kaner, Robert J., King, Christopher S., Padilla, Maria L., Noth, Imre, Scholand, Mary Beth, Shifren, Adrian, Nathan, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362639/
https://www.ncbi.nlm.nih.gov/pubmed/32664913
http://dx.doi.org/10.1186/s12890-020-01209-4

Ejemplares similares

Ejemplares similares